Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles.
In this study, we sought to develop strategies for improved endothelialization of a new polymer coating for vascular stents. Surface enhancement of the new poly-1,8-octanediol-co-citric acid (POC) polymer was achieved through conjugation of anti-CD34 antibody and incorporation of vascular endothelial growth factor and basic fibroblast growth factor-containing poly-lactic-co-glycolic acid microparticles to improve capture and proliferation of endothelial progenitor cells (EPC) and compared to untreated POC and poly-L-lactic acid (PLLA) polymer. Our results indicate that compared to PLLA, POC coating was more hemocompatible, with less platelet activation (p = 0.01), thrombogenicity (p < 0.05 for 20 and 30 min clot formation), and inflammatory response (IL-1β release, p = 0.0009; TNF-α release, p = 0.004). EPC adhesion and proliferation on POC were significantly improved with surface enhancement and microparticle incorporation compared to untreated POC (p = 0.006) and PLLA (p = 0.003). These results suggest a new strategy for enhancing endothelialization of polymeric coatings of vascular prostheses.
University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hao
H
Xu
Kytai T
KT
Nguyen
Emmanouil S
ES
Brilakis
Jian
J
Yang
Eric
E
Fuh
Subhash
S
Banerjee
D000906:Antibodies / Q000378:metabolism; D018952:Antigens, CD34 / Q000276:immunology / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D002951:Citrates / Q000737:chemistry* / Q000633:toxicity; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D042783:Endothelial Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000737:chemistry / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D019344:Lactic Acid / Q000737:chemistry* / Q000633:toxicity; D008422:Materials Testing; D019007:P-Selectin / Q000378:metabolism; D010316:Particle Size; D015539:Platelet Activation; D011091:Polyesters; D011100:Polyglycolic Acid / Q000737:chemistry* / Q000633:toxicity; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry* / Q000633:toxicity; D011474:Prosthesis Design; D013234:Stem Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D015607:Stents; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000737:chemistry / Q000494:pharmacology*
D000906:Antibodies; D018952:Antigens, CD34; D002951:Citrates; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D019007:P-Selectin; D011091:Polyesters; D011108:Polymers; C546937:SELP protein, human; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; C513817:poly(1,8-octanediol citrate); D016222:Fibroblast Growth Factor 2; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C033616:poly(lactide)